Overview

Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is an open label study of abiraterone acetate in combination with BEZ235 and abiraterone acetate in combination with BKM120 in CRPC patients with abiraterone acetate failure.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Abiraterone Acetate
Dactolisib